Report unclassified code for compounded drugs

Why This Topic Matters

Compounded drugs can be subject to special payer rules, and submitting them incorrectly can lead to claim denials or compliance concerns. The article helps readers recognize when a product may fall under compounded-drug billing policies and why carrier-specific requirements should be checked before reporting.

Article Sections

1. Compounded drugs and brand-name viscosupplementation context

   Introduces the billing concern using a compounded product example and places it in the context of viscosupplementation and other specialty drug use. It also raises the issue of whether the product fits existing payer categories.

2. Separate billing rules for compounded drugs

   Summarizes how compounded drugs are treated differently in claims processing and why payers may require additional details. The section references contractor-specific approaches and documentation expectations.

3. Payer definitions and policy considerations

   Describes general criteria used by a Medicare contractor to determine whether a drug meets the definition of a compounded product. It focuses on policy concepts and examples of when a drug may qualify.

4. Practical cautions for practices

   Offers broad cautions about verifying product status, checking for payer requirements, and avoiding assumptions about reporting methods. It emphasizes the need to review coverage guidance before billing.